Marimed (MRMD) EBITDA Margin (2011 - 2026)

Marimed (MRMD) has 16 years of EBITDA Margin data on file, last reported at 0.32% in Q1 2026.

• EBITDA Margin for Q1 2026 came in at 0.32%, up 272.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 1.03% (down 98.0% YoY), and the FY2025 annual result was 1.76%, down 342.0% from the prior year.
• EBITDA Margin improved to 0.32% in Q1 2026 per MRMD's latest filing, from 10.86% in the prior quarter.
• Over five years, EBITDA Margin peaked at 22.53% in Q1 2022 and troughed at 10.86% in Q4 2025.
• A 5-year average of 6.01% and a median of 5.33% in 2024 frame the typical range for EBITDA Margin.
• On a YoY basis, EBITDA Margin climbed as much as 475 bps in 2022 and fell as far as 2322 bps in 2022.
• A 5-year view of EBITDA Margin shows it stood at 8.62% in 2022, then dropped by 28 bps to 6.2% in 2023, then plunged by 161 bps to 3.77% in 2024, then sank by 188 bps to 10.86% in 2025, then surged by 103 bps to 0.32% in 2026.
• Business Quant data shows MRMD's EBITDA Margin at 0.32% in Q1 2026, 10.86% in Q4 2025, and 3.92% in Q3 2025.